Top Story

FDA grants orphan drug designation to BLZ-100 for brain cancer

July 7, 2015

The FDA granted orphan drug designation to BLZ-100, an agent intended to improve surgery for malignant brain tumors by providing real-time, high-resolution visualization of cancer cells, according to a press release from the drug’s manufacturer.

BLZ-100 (Blaze Bioscience) is the combination of an optide — or an optimized peptide that binds and internalizes into cancer cells — and a fluorescent dye which emits near–infrared-range light.

Meeting News Coverage

No overall improvement in mCRC PFS with Y-90 spheres, but liver-only metastases respond well

July 7, 2015
Radiation therapy using yttrium-90 resin microspheres combined with chemotherapy did not improve overall progression-free survival in patients with nonresectable…
Elisa V. Bandera, MD In the Journals

BMI should not influence chemotherapy dose reductions for ovarian cancer

July 7, 2015
Women with ovarian cancer who received paclitaxel and carboplatin dose reductions experienced poorer survival regardless of their body size, according to study…
In the Journals

Extended anticoagulation beneficial after pulmonary embolism; stops when treatment ends

July 7, 2015
Patients who experience a first pulmonary embolism may benefit from anticoagulation therapy for up to 2 years after the unprovoked episode, although the benefits of…
In the Journals

History of melanoma, actinic skin lesions linked to better use of sun protection

July 7, 2015
A recent population-based study has revealed that people with a previously confirmed melanoma diagnosis and/or treated actinic lesions were more likely to regularly use…
More News Headlines »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: Complete lymph node dissection does not improve outcomes in SLNB-positive melanoma

VIDEO: Complete lymph node dissection does not improve outcomes in SLNB-positive melanoma

June 19, 2015
CHICAGO — Vernon K. Sondak, MD, chair of the department of cutaneous oncology at Moffitt Cancer Center and a…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan